RIOT vs. VIVO, OSTK, OXFD, AWH, SOFI, COOP, CLSK, QFIN, WD, and LU
Should you be buying Riot Platforms stock or one of its competitors? The main competitors of Riot Platforms include Meridian Bioscience (VIVO), Overstock.com (OSTK), Oxford Immunotec Global (OXFD), Aspira Women's Health (AWH), SoFi Technologies (SOFI), Mr. Cooper Group (COOP), CleanSpark (CLSK), Qifu Technology (QFIN), Walker & Dunlop (WD), and Lufax (LU).
Meridian Bioscience (NASDAQ:VIVO) and Riot Platforms (NASDAQ:RIOT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, community ranking, analyst recommendations and valuation.
In the previous week, Riot Platforms had 12 more articles in the media than Meridian Bioscience. MarketBeat recorded 12 mentions for Riot Platforms and 0 mentions for Meridian Bioscience. Riot Platforms' average media sentiment score of 0.00 beat Meridian Bioscience's score of -0.49 indicating that Meridian Bioscience is being referred to more favorably in the media.
Riot Platforms has a net margin of 76.02% compared to Riot Platforms' net margin of 12.70%. Riot Platforms' return on equity of 16.74% beat Meridian Bioscience's return on equity.
Meridian Bioscience has higher revenue and earnings than Riot Platforms. Riot Platforms is trading at a lower price-to-earnings ratio than Meridian Bioscience, indicating that it is currently the more affordable of the two stocks.
Riot Platforms received 183 more outperform votes than Meridian Bioscience when rated by MarketBeat users. Likewise, 67.43% of users gave Riot Platforms an outperform vote while only 50.40% of users gave Meridian Bioscience an outperform vote.
Riot Platforms has a consensus price target of $18.15, indicating a potential upside of 86.30%. Given Meridian Bioscience's higher probable upside, analysts clearly believe Riot Platforms is more favorable than Meridian Bioscience.
Meridian Bioscience has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Comparatively, Riot Platforms has a beta of 4.19, indicating that its stock price is 319% more volatile than the S&P 500.
89.7% of Meridian Bioscience shares are owned by institutional investors. Comparatively, 40.3% of Riot Platforms shares are owned by institutional investors. 2.3% of Meridian Bioscience shares are owned by company insiders. Comparatively, 4.4% of Riot Platforms shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Riot Platforms beats Meridian Bioscience on 9 of the 17 factors compared between the two stocks.
Get Riot Platforms News Delivered to You Automatically
Sign up to receive the latest news and ratings for RIOT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RIOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Riot Platforms Competitors List
Related Companies and Tools
